



“MINDACT WAS A GREAT EXAMPLE OF ACADEMIC COLLABORATION THAT LED TO PRACTICE-CHANGING RESULTS AND IMPACTED THE LIVES OF MANY PATIENTS WITH EARLY BREAST CANCER.” DR FATIMA CARDOSO, PRINCIPAL INVESTIGATOR OF MINDACT

**MINDACT (BIG 3-04)
SPARING CHEMOTHERAPY WHEN NOT NECESSARY**

In this study involving 6,693 patients and carried out by the European Organisation for Research and Treatment of Cancer (EORTC) in close collaboration with BIG in nine countries throughout Europe, researchers showed that up to **46% of high-risk patients with early stage breast cancer could avoid chemotherapy and its likely side effects** if a sophisticated tumour genomic test (MammaPrint®) showed their cancer was unlikely to come back.

Patients were followed-up for about nine years and, in 2020, **results of the longer follow-up confirmed the utility of the MammaPrint test and the possibility to substantially and safely de-escalate the use of post-surgery chemotherapy** for some groups of patients, thereby sparing many from an unpleasant treatment and its short and long-term side effects.

MINDACT: A SUCCESSFUL ACADEMIC TRIAL THAT HELPED CHANGE CLINICAL PRACTICE

- > 47 MILLION € RAISED BY ACADEMIA TO FUND THE TRIAL
- > ALMOST 9 YEARS FOLLOW-UP OF PATIENTS
- > 6,693 PATIENTS INVOLVED FROM 112 CENTRES AND HOSPITALS IN 9 COUNTRIES
- > COMPLEX AND SUCCESSFUL LOGISTICS AND DATA MANAGEMENT

The study published its first results in 2016 in the *New England Journal of Medicine*¹, and the long-term results in the *Lancet Oncology*² in March 2021.

References:
¹ Cardoso F, van't Veer LJ, Bogaerts J, et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. *N Engl J Med* 2016; 375:717-729
https://www.nejm.org/doi/full/10.1056/NEJMoa1602253?query=recirc_curatedRelated_article
² Piccart M, van't Veer LJ, Poncet C et al. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. *The Lancet Oncology* 2021 March 12. doi:[https://doi.org/10.1016/S1470-2045\(21\)00007-3](https://doi.org/10.1016/S1470-2045(21)00007-3).
[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045\(21\)00007-3/fulltext](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00007-3/fulltext)
https://www.nejm.org/doi/full/10.1056/NEJMoa1602253?query=recirc_curatedRelated_article

MINDACT was supported by grants from the European Commission Framework Programme VI (FP6-LSHC-CT-2004-503426, “TRANSBIG Network of Excellence”), the Breast Cancer Research Foundation, Novartis, F. Hoffman La Roche, Sanofi-Aventis, Eli Lilly, Veridex, the U.S. National Cancer Institute, the European Breast Cancer Council-Breast Cancer Working Group (BCWG grant for the MINDACT biobank), the Jacqueline Seroussi Memorial Foundation (2006 JSMF award), Prix Mois du Cancer du Sein (2004 award), Susan G. Komen for the Cure (SG05-0922-02), Fondation Belge Contre le Cancer (SCIE 2005-27), Dutch Cancer Society (KWF), Association Le Cancer du Sein, Parlons-en!, the Brussels Breast Cancer Walk-Run and the American Women’s Club of Brussels, NIF Trust, Deutsche Krebshilfe, the Grant Simpson Trust and Cancer Research UK. This trial was also supported by the EORTC Charitable Trust. Whole genome analysis was provided in kind by Agendia.